Vivani Medical, Inc.

Vivani Medical announced a definitive agreement for its wholly owned subsidiary, Cortigent, to merge with a subsidiary of ClearOne, Inc. Upon consummation, Cortigent will become a wholly owned subsidiary of ClearOne, which will be renamed Cortigent Holdings, Inc. and trade under the Nasdaq ticker 'CRGT'. ClearOne will also raise $10 million to $15 million in financing. Vivani is expected to own 59.4% to 67.5% of the combined company, receiving 12.5 million shares of ClearOne. This transaction aims to reduce Vivani's direct expenditures, allow it to focus on its core drug implant business, and provide funding for Cortigent's neurostimulation technology development, including the Orion artificial vision device.

Vivani Medical, Inc. announced the appointment of August Moretti to its board of directors, effective June 26, 2026. Mr. Moretti brings extensive operating and financial executive experience and will chair the Audit Committee and serve on the Compensation Committee. Concurrently, Dr. Dean Baker retired from the board after a distinguished tenure, during which he provided critical guidance, including during the merger of Nano Precision Medical and Second Sight Medical Products.

Vivani Medical, Inc. announced it has received approval from Bellberry, an Australian human research ethics committee, to initiate SLIM-1, a Phase 1 clinical trial for NPM-139, its semaglutide implant. The trial is expected to begin in mid-2026 and will assess the safety, tolerability, and pharmacokinetics of the miniature, ultra long-acting drug implant in obese or overweight subjects. The company is also preparing for SLIM-2, a subsequent efficacy-oriented trial, aiming to accelerate the development of NPM-139.

Vivani Medical, Inc. announced that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the 2026 BIO International Convention. The presentation is scheduled for Wednesday, June 24, 2026, at 2:15 p.m. Pacific Time in Theater 3 of the San Diego Convention Center. Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, including GLP-1 based implants for metabolic diseases.

Vivani Medical, Inc. announced that its CEO, Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2026, in New York, with a replay available online afterward. Vivani is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants for metabolic diseases.

Vivani Medical reported a net loss of $6.8 million for the first quarter ended March 31, 2026, an increase from $6.3 million in the prior year. The company announced it is on track to initiate its SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant for chronic weight management, by mid-2026, with top-line results expected by year-end. Vivani Medical also stated it has $28 million in cash and capital commitments, providing a runway to fund operations through the first half of 2027, and continues to explore options for its Cortigent neuromodulation assets.

Vivani Medical, Inc. reported a net loss of $(6.78) million for the first quarter of 2026, an increase from $(6.30) million in the prior year period. However, net loss per common share improved to $(0.08) from $(0.11) due to increased shares outstanding. The company significantly bolstered its liquidity by raising $9.71 million through various financing activities, including private sales and a registered direct offering. Despite these capital infusions, Vivani Medical continues to operate on a going concern basis, projecting its current cash to last through the second quarter of 2027 and emphasizing the need for additional funding thereafter.

Vivani Medical, Inc. reported its first-quarter 2026 financial results and provided a business update, confirming the initiation of its SLIM-1™ Phase 1 clinical trial for NPM-139 (a semaglutide implant for weight management) is on track for mid-2026, with top-line results expected by year-end. The company also announced a strong financial position with $28 million in cash and commitments, providing a runway through the first half of 2027. Additionally, Vivani is progressing with its next-generation implant and exploring options for its neuromodulation subsidiary, Cortigent, to become an independent public company.

Vivani Medical, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 24, 2026. Stockholders will vote on key proposals including the election of six directors, a non-binding advisory vote on executive compensation, and the adoption of an amended incentive plan. The meeting will also address the ratification of BPM LLP as the independent auditor for the fiscal year ending December 31, 2026, with the record date for voting set for April 27, 2026.